Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | NPC1 | O15118 | 3/20 | 0.75 |
| ▸ | RAB9A | P51151 | 3/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31601891 | 0.88 | SMN1; SMN2 (0.77) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL18462700 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL19682978 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL3098051 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL203916 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL5726571 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL5752708 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL188053 | 0.86 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL205216 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL9962352 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563722-B2 | Stereoselective hydrogenation of a ketone | GLAXO GROUP LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-20110306765-A1 | STEREOSELECTIVE HYDROGENATION OF A KETONE | GLAXO GROUP LIMITED (GB) | 2011-12-15 | — | — | US | disclosed |
| WO-2010099098-A1 | STEREOSELECTIVE HYDROGENATION OF A KETONE | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| EP-1131314-A4 | COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6350744-B1 | PYRMIDINE OR PYRIDINE DERIVATIVES; ANTIARTHRITIC AND ANTIINFLAMMATORY AGENTS; CACHEXIA TREATMENT; INTERLEUKIN AND TUMOR NECROSIS FACTOR INHIBITORS | MERCK & CO., INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1131314-A1 | COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY | Merck & Co., Inc. (US) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031065-A1 | COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO., INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-1997016442-A1 | SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306765-A1 | STEREOSELECTIVE HYDROGENATION OF A KETONE | CCR2, CX3CR1, CCR1 | SMN1; SMN2 4690/4885NPC1 2617/4885RAB9A 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.